Pipeline therapeutics. People with these diseases often face limited options.

Pipeline therapeutics. Apr 19, 2023 · Pipeline Therapeutics is collaborating with a branch of Janssen Pharmaceuticals to advance PIPE-307, a potential oral treatment of nervous system conditions that is expected to enter a clinical Apr 17, 2023 · PIPE-307 is an oral, highly selective antagonist of the muscarinic M1 receptor, which has completed two Phase 1 clinical trials in healthy patients and has received Investigational New Drug clearance from the Food and Drug Administration (FDA) to initiate clinical development in relapsing-remitting multiple sclerosis (RRMS) patients. We are pioneering new therapies for conditions at the intersection of NI&I. . People with these diseases often face limited options. Pipeline Therapeutics will receive $50M upfront and up to $1B in milestones and royalties from Janssen. Pipeline Therapeutics is a developer of regenerative therapies designed to promote functional recovery of neurological diseases. We are primarily developing treatments with clinically validated biological targets to address these serious diseases—altering the pathways that drive them. Information about our Innovative Medicine patent portfolio. Apr 18, 2023 · Janssen will receive an exclusive global licence for the research, development and commercialisation of PIPE-307 in all indications, while Pipeline will have the right to advance the therapy into a Phase II clinical trial to treat RRMS. Major US/EU approvals and submissions and phase 2/3 clinical data presentations being planned or achieved for the year. Apr 17, 2023 · PIPE-307 is an oral compound that targets the M1 muscarinic receptor to treat nervous system disorders, including relapsing-remitting multiple sclerosis. yexcuvll aqq dsshw pjkv vckt tth ntph zeqei vpe cgtjj